EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

mRNA-based technology for engineered regenerative medicine

Xueyan Zhen, Wei Chen, Wei Tao

Cell Biomaterials · 2026-01 · 2 (1) · 100185

DOI: 10.1016/j.celbio.2025.100185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biomaterials, 2026-01. Verfasst von Xueyan Zhen und 2 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LEO Fondet, American Heart Association, American Society of Transplantation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regenerative medicine presents a transformative approach to repairing or replacing damaged tissues and organs. While traditional gene therapies hold relatively long-lasting expression, concerns such as genomic integration risks, high costs, and regulatory complexities have limited their clinical application. The success of messenger RNA (mRNA) vaccines has introduced mRNA technology as a promising therapeutic platform, providing a potentially safe and translatable intervention for regenerative medicine. In this review, we provide deep insights into the advances in regenerative therapies with a focus on rationally designed mRNA techniques. We highlight mRNA-mediated strategies, including protein supplementation, cell reprogramming, and cell transdifferentiation, which enable precise control over cell fate. These modalities, driven by innovations in mRNA synthesis, chemical modifications, and nano-delivery platforms, mobilize cells by redirecting their differentiation toward specific types. Finally, we propose an integrated overview of preclinical and clinical progress, addressing challenges and the transformative potential of mRNA technology for clinical translation in engineered regenerative medicine.

Förderung

  • LEO Fondet
  • American Heart Association
  • American Society of Transplantation
  • Harvard University
  • Novo Nordisk
  • American Lung Association
  • U.S. Department of Defense

Zitieren

APA

Zhen, X., Chen, W., & Tao, W. (2026). mRNA-based technology for engineered regenerative medicine. Cell Biomaterials, 2(1), 100185. https://doi.org/10.1016/j.celbio.2025.100185

Vancouver

Zhen X, Chen W, Tao W. mRNA-based technology for engineered regenerative medicine. Cell Biomaterials. 2026;2(1):100185. doi:10.1016/j.celbio.2025.100185

BibTeX
@article{Zhen2026,
  author = {Zhen, Xueyan and Chen, Wei and Tao, Wei},
  title = {mRNA-based technology for engineered regenerative medicine},
  journal = {Cell Biomaterials},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {100185},
  doi = {10.1016/j.celbio.2025.100185}
}
Kostenlos starten →